Dr. Casey F. Jeffreys, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 427
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NC license 2018-00730
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wakemed, Raleigh Campus Raleigh, NC
- Wakemed, Cary Hospital Cary, NC
Medical groups
- Raleigh Neurology Associates, P. A. (52 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 427
- Services billed
- 51,361
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, ocrelizumab, 1 mg | 9,300 | 13 |
| Injection, natalizumab, 1 mg | 8,700 | 17 |
| Injection, gadobutrol, 0.1 ml | 4,200 | 44 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1,970 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 149 | 113 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 122 | 20 |
| Established patient office or other outpatient visit, 40-54 minutes | 83 | 65 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 58 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 52 | 52 |
| Administration of chemotherapy into vein, 1 hour or less | 51 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Raleigh, NC | 323 |
| Baclofen Other prescribers in Raleigh, NC | 308 |
| Donepezil Hcl Other prescribers in Raleigh, NC | 148 |
| Duloxetine Hcl Other prescribers in Raleigh, NC | 130 |
| Memantine Hcl Other prescribers in Raleigh, NC | 114 |
| Levetiracetam Other prescribers in Raleigh, NC | 113 |
| Tizanidine Hcl Other prescribers in Raleigh, NC | 106 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Raleigh, NC | 96 |
| Topiramate Other prescribers in Raleigh, NC | 89 |
| Kesimpta Pen (ofatumumab) | 89 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 190 payments worth $13,318 in total to this clinician.
| EMD Serono, Inc. | $7,307 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,275 |
| Tg Therapeutics, Inc. | $764 |
| Alexion Pharmaceuticals, Inc. | $384 |
| AbbVie Inc. | $297 |
| Celgene Corporation | $256 |
| Biogen, Inc. | $192 |
| Boston Scientific Corporation | $180 |
| Consulting Fee | $9,400 |
|---|---|
| Food and Beverage | $3,918 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. Jan 7, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionAdvisory Board Participation (Fee For Service) | $7,200 |
| Novartis Pharmaceuticals Corporation Jun 13, 2025 | Consulting Fee KESIMPTA · Neurology | $2,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $787,355 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse
Novartis Pharmaceuticals Corporation - A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, F…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.